RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
Official title: RAPID: A patient-centric, investigator-initiated, Bayesian-designed, open-label, phase 2 platform trial of promising drugs for AYA patients with relapsed/refractory Ewing sarcoma & DSRCT.
Funded at University of Tx Md Anderson Can Ctr · NIH-11440318 · Data updated 2026-11-12
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $899,917 |
| NIH project number | 1R01FD008794-01 |
| Project ID | NIH-11440318 on NIH RePORTER |
Who could benefit from this research
✓Could help
AYA patients (adolescents and young adults) with relapsed or refractory Ewing sarcoma or desmoplastic small round cell sarcoma.
✕Less likely to help
Patients enrolling in a trial with ineffective or unsafe drug combinations may not experience benefit and could face risks from adverse events.
What this research studies
This program uses a flexible, Bayesian-designed platform to test multiple drug combinations in a small, ultra-rare patient group. It emphasizes a patient-centric approach, aiming to work closely with drug developers and regulators to move safe, potentially effective regimens into practice faster. The trial seeks to collect molecular profiling data to tailor treatments and improve decision-making for future therapies. Participants will receive investigational or repurposed drugs in combination, with ongoing safety monitoring and adaptive decision rules.
Why it matters
Potential benefit: If successful, patients could access effective drug combinations earlier and contribute to knowledge that may improve outcomes for future ES and DSRCT patients.
How similar studies have gone: Prior platform and adaptive trials in rare cancers have shown potential to identify active regimens more quickly, though this exact approach is early in development.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Ludwig, Joseph a — University of Tx Md Anderson Can Ctr
- Study coordinator: Ludwig, Joseph a
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
-
Novel OTUD7A inhibitors to treat Ewing sarcoma
A scientist team is developing new small-molecule drugs that block OTUD7A to slow or stop Ewing sarcoma in children and young adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.